A fifth locus for otosclerosis, *OTSC5*, maps to chromosome 3q22–24

K Van Den Bogaert, E M R De Leenheer, W Chen, Y Lee, P Nürnberg, R J E Pennings, K Vanderstraeten, M Thys, C W R J Cremers, R J H Smith, G Van Camp

J Med Genet 2004;41:450–453. doi: 10.1136/jmg.2004.018671

Otosclerosis is caused by abnormal bone homeostasis of the otic capsule leading to bony fixation of the stapedial footplate in the oval window. Because the transmission of sound waves from outer to inner ear is disturbed by this fixation, the disease is characterised by conductive hearing impairment.¹ In some cases, an additional sensorineural component develops across all frequencies, leading to mixed hearing impairment.^{2,3} The conductive component of the hearing impairment can be restored by stapes replacing microsurgery; however, the sensorineural component cannot surgically be corrected.⁴

Otosclerosis has a prevalence of 0.3–0.4% in the Caucasian population.⁵ The etiology of the disease is unknown, but epidemiological studies indicate the involvement of genetic as well as environmental factors. However, large families segregating otosclerosis are very rare, whereas there are frequent sporadic cases and smaller families with only a few affected members. Based on these findings, otosclerosis can be considered a genetically complex disease, caused by an interaction of genes and environmental factors, but with rare monogenic forms.

To date, three autosomal dominant otosclerosis loci have been reported: *OTSC1* on chromosome 15q25–26,⁶ *OTSC2* on chromosome 7q34–36,⁷ and *OTSC3* on chromosome 6p21–22.⁸ In addition, a fourth locus, *OTSC4*, has been reserved by the Human Genome Organisation nomenclature committee, but this has not been published. None of the corresponding genes have been cloned. In this study, we identified a large Dutch family segregating an autosomal dominant otosclerosis. After exclusion of the known loci, a genome-wide screen and linkage analysis in this family revealed the existence of a fifth otosclerosis locus, *OTSC5*, localised on chromosome 3q22–24.

METHODS

Clinical diagnosis

The family was identified via the Department of Otorhinolaryngology of the University Medical Center St.-Radboud Nijmegen (The Netherlands) (fig 1). Pure-tone audiometry was performed in all persons with air conduction at 125, 250, 500, 1000, 2000, 4000, and 8000 Hz, and bone conduction at 250, 500, 1000, 2000, and 4000 Hz. Tympanic membrane compliance and ipsi- and contralateral stapedial reflex decay were also measured. Individuals in whom stapes fixation with an otosclerotic focus was confirmed during stapes replacing microsurgery were considered affected. In non-operated persons, the clinical diagnosis of otosclerosis was based on audiologic data. Persons with a conductive or mixed hearing loss together with absent or immeasurable stapedial reflexes were classified as affected. Due to the variability of the age of onset, only family members >50 years of age and with normal hearing were considered

Key points

- Otosclerosis, a bone disorder of the otic capsule, is the most common cause of hearing impairment among white adults with a prevalence of 0.3–0.4%. The etiology of the disease is unknown, but there are strong suggestions that genetic as well as environmental factors may be involved.
- To date, three autosomal dominant otosclerosis loci (*OTSC1* on chromosome 15q25–26, *OTSC2* on chromosome 7q34–36, and *OTSC3* on chromosome 6p21–22) have been reported, while a fourth locus, *OTSC4*, has been reserved. None of the responsible genes have been cloned.
- In this study, a fifth locus, *OTSC5*, was localised on chromosome 3q22–24 by linkage analysis in a Dutch pedigree segregating autosomal dominant otosclerosis. Recombinant individuals delineate a 15.5 Mb candidate interval between the markers D3S1292 centromeric and D3S1744 telomeric.
- In the future, refinement of the candidate region and mutation analysis of candidate genes will lead to the identification of the disease-causing gene in this family.

‘unaffected’. Information on deceased members of the pedigree was obtained by history.

Genotype analysis

Blood samples from study participants were obtained after informed consent and were used as a source of genomic DNA, which was isolated using standard techniques. The microsatellite markers used to analyse linkage to the known otosclerosis loci were D15S652, D15S1004, and D15S657 for *OTSC1*, D7S495, D7S2560, D7S684, D7S2513, and D7S2426 for *OTSC2*, and D6S1588, D6S273, D6S291, D6S1680, and D6S426 for *OTSC3*. Information for all markers was taken from The Genome Database (<http://www.gdb.org/>).

A genome-wide screen was performed by fluorescence-based semi-automated genotyping using 380 microsatellite markers selected from the final Génethon linkage map⁹ with an average heterozygosity of 0.76. For fine mapping of the candidate region additional microsatellite markers were selected from public databases. After individual PCR amplification on an MJ Research thermocycler, PCR products were pooled and size fractionated by electrophoresis on a Prism ABI 3700 DNA sequencer (Applied Biosystems). Allele sizes were determined using GENESCAN 2.1.1. and Genotyper V3.7 software (Applied Biosystems).

Linkage analysis

All genotypes were checked for Mendelian inconsistencies using LINKRUN software (Wienker, unpublished). Two-point LOD scores were calculated between each marker locus and otosclerosis under the assumption of an autosomal dominant model with 90% penetrance, a phenocopy rate of 1%, a frequency of 0.0001 for the disease allele, and equal allele frequencies for each marker using LINKAGE V5.21 software.¹⁰ Equal recombination frequencies between males and females were assumed.

Mutation analysis

Primers were designed from intronic sequences flanking the exons of *PCOLCE2* and *CHST2* to amplify genomic DNA from patient and control individuals. Direct sequencing of the PCR product was performed on both forward and reverse strands on an ABI 3100 sequencer using the Dyanamic™ ET Terminator Cycle Sequencing Kit (Amersham Biosciences).

RESULTS AND DISCUSSION

Clinical analysis

The family presented in this study segregates an autosomal dominant otosclerosis (fig 1) in eight of 10 affected members confirmed by stapes replacing microsurgery. In the two remaining subjects (III:11 and III:12), the presence of an air-bone gap, closing at a frequency of 2000 Hz, together with the absence of stapedal reflexes clinically confirmed the diagnosis of otosclerosis. Nine family members and one spouse had normal hearing.

Genetic analysis

Initially, genetic analysis was performed on 18 family members, of whom 10 were affected and seven unaffected, with one unaffected spouse (fig 1). Statistically significant exclusion of the three known otosclerosis loci was demonstrated (table 1). A genome-wide screen in this family

revealed suggestive linkage at chromosome region 3q22–24, from which a maximum two-point LOD score of 2.98 was obtained for marker D3S1569 at $\theta = 0.05$. Two additional unaffected subjects were identified (III:14 and III:18). After genotyping these individuals for markers in the region of interest, a maximum two-point LOD score of 3.46 was obtained for marker D3S1569 at $\theta = 0.05$ (table 2). Haplotypes were constructed to confine the interval of the linked region. A recombination event in individuals III:5 and III:9 placed the disease locus proximal to D3S1744, while a recombination event in individuals III:12 and III:13 mapped the disease-causing gene distal to D3S1292. Hence, the maximal interval of linkage with the otosclerosis phenotype is bordered by D3S1292 (centromeric) and D3S1744 (telomeric) within a region of ~15.5 Mb, according to the last draft of the human genome sequence (Build 34 Version 1). A physical map of the candidate region is presented in figure 2.

Individual III:2, who in the linkage analysis was considered to be affected, does not carry the haplotype segregating with the disease in the other patients. Because he underwent bilateral stapes replacing microsurgery, he could be considered to be a phenocopy. In view of the high frequency of otosclerosis in the white population, the presence of a phenocopy in an otosclerosis family is not surprising. Alternatively, this could reflect an unrecognised double crossover, which is extremely unlikely, given the small intermarker distances.

The 15.5 Mb *OTSC5* interval contains 59 identified genes and 45 gene predictions. Two genes were considered very good otosclerosis candidate genes: *PCOLCE2* and *CHST2*. The *PCOLCE2* (procollagen COOH-terminal proteinase enhancer protein 2) gene product is found to be a glycoprotein that binds the COOH-terminal propeptide of type I procollagen and is highly expressed in non-ossified cartilage in developing tissues.¹¹ The otic capsule is unique in retaining calcified

Figure 1 Pedigree of the Dutch family with autosomal dominant otosclerosis, showing the most likely haplotypes for the chromosome 3 markers. The haplotype linked to otosclerosis is indicated with a black bar.

Figure 2 Localisation of *OTSC5* on chromosome 3q22–24. The black bar indicates the region that contains the gene for otosclerosis.

cartilage, known as globuli interossei, throughout life and in lacking bone remodelling. Because these factors are unique to the otic capsule they may predispose to otosclerosis. The expression pattern of *PCOLCE2* suggests a possible role for this gene in the pathogenesis. The *CHST2* (carbohydrate sulfotransferase 2) gene product is a Golgi-associated sulfotransferase. These sulfotransferases sulfonate glycoproteins,

glycosaminoglycans, peptidyl tyrosine, and heparan sulfates and play important roles in intercellular communication.¹² Because otosclerosis has been hypothesised to result from a disorder of the extracellular matrix of the cartilaginous rests present in the adult temporal bone, the clear relationship of *CHST2* to extracellular matrix function makes this gene a strong candidate gene. However, mutation analysis of the

Table 1 Two-point LOD scores between otosclerosis and the known otosclerosis loci *OTSC1*, *OTSC2*, and *OTSC3*

Locus	Marker	Recombination fraction (θ)						
		0.0	0.01	0.05	0.1	0.2	0.3	0.4
OTSC1	D15S652	-6.67	-4.68	-2.88	-1.88	-0.80	-0.27	-0.04
	D15S1004	-5.57	-4.57	-2.83	-1.83	-0.81	-0.31	-0.07
	D15S657	-0.03	-0.01	0.05	0.09	0.13	0.12	0.07
OTSC2	D7S495	-5.57	-3.91	-2.56	-1.72	-0.76	-0.29	-0.06
	D7S2560	-3.91	-2.19	-0.93	-0.31	0.19	0.28	0.13
	D7S684	-1.48	-0.13	0.46	0.64	0.63	0.42	0.14
	D7S2513	-4.36	-2.86	-1.84	-1.19	-0.44	-0.10	0.00
OTSC3	D7S2426	-4.04	-2.51	-1.40	-0.87	-0.38	-0.15	-0.04
	D6S1588	-0.71	-0.63	-0.37	-0.18	0.00	0.04	0.02
	D6S273	-1.06	-0.99	-0.75	-0.50	-0.18	-0.05	-0.02
	D6S291	-2.41	-2.07	-1.41	-0.99	-0.58	-0.33	-0.13
	D6S1680	-2.70	-2.31	-1.54	-1.05	-0.51	-0.21	-0.05
	D6S426	-4.10	-3.48	-2.30	-1.50	-0.63	-0.22	-0.05

Table 2 Two-point LOD scores between otosclerosis and chromosome 3 markers (*OTSC5*)

Marker	Recombination fraction (θ)						
	0.0	0.01	0.05	0.1	0.2	0.3	0.4
D3S1558	-1.23	-0.96	-0.54	-0.32	-0.13	-0.05	-0.01
D3S1303	-3.74	-2.24	-0.98	-0.38	0.09	0.17	0.08
D3S1292	-1.29	-0.25	0.72	1.05	1.07	0.75	0.29
D3S3554	2.18	2.31	2.43	2.31	1.83	1.18	0.45
D3S1569	3.13	3.33	3.46	3.28	2.64	1.78	0.78
D3S1744	1.14	1.42	1.82	1.93	1.71	1.20	0.53

coding region and the intron–exon boundaries of both genes did not reveal any disease-causing mutation.

Identification of new otosclerosis loci will increase the possibility of detecting the first otosclerosis-causing gene in the near future. Identification of this first gene will probably facilitate the identification of the causative genes localised in the other known otosclerosis loci. Characterisation of these genes will give us increased knowledge regarding the underlying molecular pathway of otosclerosis and of the otic capsule in general.

ACKNOWLEDGEMENTS

We thank the family members for their cooperation, and Inka Szangolies, Regina Pospiech, and Gudrun Nürnberg for excellent technical support. KVDB holds a predoctoral research position with the Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT-Vlaanderen). This research was performed in the framework of the Interuniversity Attraction Poles program P5/19 of the Belgian Federal Science Policy Office.

Authors' affiliations

K Van Den Bogaert, K Vanderstraeten, M Thys, G Van Camp, Department of Medical Genetics, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium

E M R De Leenheer, R J E Pennings, C W R J Cremers, Department of Otorhinolaryngology, University Medical Center St Radboud, Philips van Leydenlaan 15, 6500 HB Nijmegen, The Netherlands

E M R De Leenheer, Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium

W Chen, R J H Smith, Molecular Otolaryngology Research Laboratories, Department of Otolaryngology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA

Y Lee, P Nürnberg, Gene Mapping Center (GMC), Max Delbrueck Center for Molecular Medicine (MDC) Berlin-Buch, Robert-Roessler-Strasse 10, D-13092 Berlin, Germany

This study was supported in part by NIH grant R01DC05218 (RJHS, GVC), and grants from the University of Antwerp (GVC) and from the Vlaams Fonds voor Wetenschappelijk Onderzoek (FWO) (GVC).

Conflict of interest: none declared.

Correspondence to: Guy Van Camp, Department of Medical Genetics, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium; Guy.VanCamp@ua.ac.be

Received 21 January 2004

REFERENCES

- Hueb MM, Goycoolea MV, Paparella MM, Oliveira JA. Otosclerosis: the University of Minnesota Temporal Bone Collection. *Otolaryngol Head Neck Surg* 1991;**105**:396–405.
- Browning GG, Gatehouse S. Sensorineural hearing loss in stapedial otosclerosis. *Ann Otol Rhinol Laryngol* 1984;**93**:13–6.
- Ramsay HAW, Linthicum FH. Mixed hearing loss in otosclerosis: indication for long-term follow-up. *Am J Otol* 1994;**15**:536–9.
- Somers T, Govaerts PJ, Janssens de Varebeke S, Offeciers E. Revision stapes surgery. *J Laryngol Otol* 1997;**111**:233–9.
- Declau F, Qiu JP, Timmermans JP, Van Spaendonck M, Michaels L, Van de Heyning P. Prevalence of otosclerosis in a non-selected series of temporal bones. *Otol Neurotol* 2001;**22**:596–602.
- Tomek MS, Brown MR, Mani SR, Ramesh A, Srisailapathy CRS, Coucke P, Zbar RIZ, Bell AM, McGuirt WT, Fukushima K, Willems PJ, Van Camp G, Smith RJH. Localization of a gene for otosclerosis to chromosome 15q25–q26. *Hum Mol Genet* 1998;**7**:285–90.
- Van Den Bogaert K, Govaerts PJ, Schatteman I, Brown MR, Caethoven G, Offeciers FE, Somers T, Declau F, Coucke P, Van de Heyning P, Smith RJH, Van Camp G. A second gene for otosclerosis (*OTSC2*) maps to chromosome 7q34–36. *Am J Hum Genet* 2001;**68**:495–500.
- Chen W, Campbell CA, Green GE, Van Den Bogaert K, Komodakis C, Manolidis LS, Aconomou E, Kyamides Y, Christodoulou K, Faghel C, Giguère CM, Alford RL, Manolidis S, Van Camp G, Smith RJH. Linkage of otosclerosis to a third locus (*OTSC3*) on human chromosome 6p21.2–22.3. *J Med Genet* 2002;**39**:473–7.
- Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissensbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. *Nature* 1996;**380**:152–4.
- Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. *Proc Natl Acad Sci U S A* 1984;**81**:3443–6.
- Steiglitz BM, Keene DR, Greenspan DS. PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1. *J Biol Chem* 2002;**277**:49820–30.
- Li X, Tedder TF. CHST1 and CHST2 sulfotransferases expressed by human vascular endothelial cells: cDNA cloning, expression, and chromosomal localization. *Genomics* 1999;**55**:345–7.